New trial
Phase I/II trial of Pemigatinib FGFR1-3 inhibitor in advanced cholangiocarcinoma
- Trial ID
- NCT06439485 on ClinicalTrials.gov
- Cancer type
- Cholangiocarcinoma
- Stage of research
- Exploratory
- Published in
- New in Oncology - June 27, 2025
This study, sponsored by M.D. Anderson Cancer Center, evaluates pemigatinib combined with atezolizumab and bevacizumab in patients with unresectable, advanced cholangiocarcinoma harboring FGFR2 fusion. The trial features a dose-escalation phase followed by expansion at the recommended dose to assess safety and preliminary efficacy.
More in liver and bile duct cancer
-
New trial · Sep 17, 2026 · NCT07793253
Phase 2 daraxonrasib pan-RAS(ON) tri-complex inhibitor targets KRAS-mutant biliary tract cancer. -
Trial result · Sep 10, 2026 · NCT05301842
STRIDE (durvalumab + tremelimumab) + VEGFR/FGFR TKI lenvatinib + TACE extends PFS in embolisation-eligible HCC -
New trial · Sep 10, 2026 · NCT07780838
Phase 2a pemigatinib FGFR1/2/3 inhibitor alternated with durvalumab PD‑L1 blockade -
New trial · Sep 3, 2026 · NCT07766187
Phase 2 durvalumab PD-L1 inhibitor plus histotripsy non-thermal focused ultrasound ablation in iCCA -
New trial · Aug 27, 2026 · NCT07723534
Phase 2 zolbetuximab CLDN18.2-directed monoclonal antibody + CAPOX/mFOLFOX6 in BTC